How These Biotech Stocks are Faring? -- Pluristem Therapeutics, BioLine Rx, GenVec, and Diffusion Pharma

Friday, April 28, 2017 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, April 28, 2017 /PRNewswire/ --

Stock-Callers.com today explores the Biotech space, which broadly segments

into the medical and agricultural markets. Although enterprising biotechnology is also being applied to other exciting areas, like industrial production of chemicals and bioremediation, the use in these areas is still specialized and limited. Under assessment
this morning are: Pluristem Therapeutics Inc. (NASDAQ: PSTI), BioLine Rx Ltd (NASDAQ: BLRX), GenVec Inc. (NASDAQ: GNVC), and Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN). Register now and get full and free access to our downloadable research reports on these stocks at:

http://stock-callers.com/registration

Pluristem Therapeutics  

On Thursday, shares in Haifa, Israel-based Pluristem Therapeutics Inc. recorded a trading volume of 161,213 shares. The stock ended at $1.45, up 0.69% from the last trading session. The Company's shares have gained 21.85% in the last one month, 29.46% over the previous three months, and 1.40% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 15.02% and 0.48%, respectively. Furthermore, shares of Pluristem Therapeutics, which through its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel, have a Relative Strength Index (RSI) of 61.89.

On April 19th, 2017, Pluristem Therapeutics announced that it was issued its 100th patent - an important milestone attesting to the significant accomplishments of the Company's scientists and engineers, as well as its enduring commitment to innovative research and development. The Company's 100 approved patents and over 110 pending patent applications cover over 30 different innovations. Access our complete research report on PSTI for free at:

http://stock-callers.com/registration/?symbol=PSTI

BioLine Rx  

Jerusalem, Israel headquartered BioLine Rx Ltd's stock finished yesterday's session 0.29% lower at $0.87 with a total trading volume of 294,575 shares. The Company's shares are trading below their 200-day moving average by 12.62%. Shares of the Company, which engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs, have an RSI of 36.11.

On April 05th, 2017, BioLine Rx announced that the Company has closed its previously announced underwritten public offering of approximately 33.8 million American Depositary Shares ("ADS"), each representing one of its ordinary shares, at a public offering price of $0.85 per ADS, for gross proceeds of $28.75 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The complimentary research report on BLRX can be downloaded at:

http://stock-callers.com/registration/?symbol=BLRX

GenVec  

At the close of trading on Thursday, shares in Gaithersburg, Maryland-based GenVec Inc. climbed 0.62%, ending the day at $6.45. The stock recorded a trading volume of 45,633 shares, which was above its three months average volume of 43,800 shares. The Company's shares have advanced 3.86% in the last one month, 1.10% in the previous three months, and 100.93% since the start of this year. The stock is trading 0.54% and 23.67% above its 50-day and 200-day moving averages, respectively. Moreover, shares of GenVec, which focuses on developing a pipeline of therapeutics and vaccines through its proprietary AdenoVerse gene delivery platform in the US, have an RSI of 56.61. Register for free on Stock-Callers.com and get access to the latest PDF format report on GNVC at:

http://stock-callers.com/registration/?symbol=GNVC

Diffusion Pharma  

Charlottesville, Virginia headquartered Diffusion Pharmaceuticals Inc.'s shares ended the day 2.33% lower at $2.94 with a total trading volume of 22,508 shares. The stock has gained 30.09% on an YTD basis. The Company's shares are trading 8.87% below their 50-day moving average. Additionally, shares of Diffusion Pharma, which focuses on developing products for ophthalmology, oncology, and dermatology, have an RSI of 46.34.

On April 04th, 2017, Diffusion Pharma announced that a key patent has been issued by the US Patent and Trademark Office on March 28th, 2017 for its lead drug candidate trans sodium crocetinate (TSC). The patent, entitled "Bipolar Trans Carotenoid Salts and Their Uses," expands coverage of the therapeutic use of TSC and other related compounds to five hypoxia-related conditions including congestive heart failure, chronic renal failure, acute lung injury, chronic obstructive pulmonary disease, and respiratory distress syndrome.  Download your free research report on DFFN at:

http://stock-callers.com/registration/?symbol=DFFN

--

Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY 

SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

http://stock-callers.com/legal-disclaimer/

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number:  +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook